Does body mass index influence the response to infliximab in ankylosing spondylitis?
This study provides the first evidence that a high BMI negatively influences the response to IFX in AS. Further prospective studies, including assessment of the fat mass, pharmacokinetics, and adipokines dosages are mandatory to elucidate the role of obesity in AS IFX response.
Advanced prospective studies should aim to define cut-point values of CD44s expression for separating aggressive tumours from their indolent counterparts, and should also assess possible associations with clinical follow-up data (e.g. progression-free survival) in IPC.